Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.

Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas

The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.

Samsung Bioepis and partner Sandoz have won approval for a third US Stelara biosimilar. Meanwhile, in Europe Celltrion has become the latest firm to qualify for an ustekinumab marketing authorization.